Blockade of cannabinoid 1 receptor improves glucose responsiveness in pancreatic beta cells. Issue 4 (12th February 2018)

• Record Type: Journal Article
• Authors: Shin, Hanho; Han, Ji Hye; Yoon, Juhwan; Sim, Hyo Jung; Park, Tae Joo; Yang, Siyoung; Lee, Eun Kyung; Kulkarni, Rohit N.; Egan, Josephine M.; Kim, Wook
• Is Part Of: Journal of cellular and molecular medicine. Volume 22:Issue 4(2018)
• Page Start: 2337
• Page End: 2345
• Publication Date: 2018-02-12
• Subjects: β‐cell function -- cannabinoid 1 receptor -- glucokinase -- glucose transporter 2 -- insulin secretion; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.13523
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Cannabinoid 1 receptors (CB1Rs) are expressed in peripheral tissues, including islets of Langerhans, where their function(s) is under scrutiny. Using mouse β‐cell lines, human islets and CB1R‐null ( CB1R −/− ) mice, we have now investigated the role of CB1Rs in modulating β‐cell function and glucose responsiveness. Synthetic CB1R agonists diminished GLP‐1‐mediated cAMP accumulation and insulin secretion as well as glucose‐stimulated insulin secretion in mouse β‐cell lines and human islets. In addition, silencing CB1R in mouse β cells resulted in an increased expression of pro‐insulin, glucokinase (GCK) and glucose transporter 2 (GLUT2), but this increase was lost in β cells lacking insulin receptor. Furthermore, CB1R −/− mice had increased pro‐insulin, GCK and GLUT2 expression in β cells. Our results suggest that CB1R signalling in pancreatic islets may be harnessed to improve β‐cell glucose responsiveness and preserve their function. Thus, our findings further support that blocking peripheral CB1Rs would be beneficial to β‐cell function in type 2 diabetes.